Retatrutide FDA approval status

Confirmed vs expected

The steps between here and a prescription

1. Complete Phase 3 trials. Five TRIUMPH trials have read out positive; Lilly says TRIUMPH-2 and TRIUMPH-3 complete the data package for global submissions.
2. Submit to the FDA. Planned for Q1 2027 (Lilly guidance). One open question is the application type: Lilly plans a BLA (biologic); the FDA classifies retatrutide as a drug requiring an NDA — a dispute in litigation since Sept 2024. Under an NDA, market exclusivity would be 5 years.
3. FDA review. A standard review commonly runs about 10 months; priority pathways can be much faster (Lilly's orforglipron was approved 54 days after filing under a National Priority Voucher).
4. Approval, labeling and launch. Manufacturing scale-up determines real-world availability.

Until then, the only legitimate access routes are clinical trials and Lilly's expanded access program (your physician must apply and medical criteria must be met).

Milestone timeline

1. Q1 2027RegulatoryExpected
   U.S. FDA submission (planned)

   Lilly plans to submit retatrutide to the FDA in Q1 2027; the date moved from "by end of 2026" to finish the manufacturing/quality (CMC) package.

   BioPharma Dive — FDA submission plans
2. Late 2026CompetitorExpected
   FDA decision expected on CagriSema (competitor)

   Novo Nordisk filed CagriSema in Dec 2025 and expects an FDA decision by late 2026.

   Novo Nordisk — CagriSema filing
3. ~Dec 2026TrialExpected
   TRIUMPH-5 (vs tirzepatide) results

   The head-to-head trial against tirzepatide (NCT06662383); completion expected around Dec 2026 (third-party estimate).

   ClinicalTrials.gov — TRIUMPH-5 (NCT06662383)
4. Sept 1, 2026Enforcement
   FDA posts warning letters to five peptide sellers

   Letters dated Aug 24, 2026, posted Sept 1, naming sellers of illicit retatrutide products.

   FDA warning letters (GLP-1 Solution; Gram Peptides)
5. Aug 12, 2026Legal
   Lilly sues six U.S. sellers of illicit retatrutide

   Defendants include a med spa, a compounding pharmacy and peptide sellers. Lilly says it has flagged 200+ entities to FDA and reported 14,000+ listings.

   CNBC — Lilly lawsuits (Aug 12, 2026)
6. Aug 3, 2026Access
   Lilly opens expanded access program

   For patients who meet medical criteria and cannot join a trial; the treating physician must apply.

   STAT — Lilly expanded access (Aug 3, 2026)
7. Jul 23, 2026Trial
   TRIUMPH-2 and TRIUMPH-3 topline results

   TRIUMPH-2 (obesity + T2D): up to 20.8% weight loss at 80 weeks. TRIUMPH-3 (severe obesity + CVD): up to 22.6%. Lilly says these complete the data package for global submissions.

   Lilly — TRIUMPH-2/TRIUMPH-3 results
8. Jun 2026Trial
   TRIUMPH-1 full results presented at ADA

   Full 80-week results presented at the American Diabetes Association meeting.

   Lilly/PR Newswire — TRIUMPH-1 results
9. May 21, 2026Trial
   TRIUMPH-1 topline: 28.3% at 80 weeks (12 mg)

   Pivotal Phase 3 obesity trial (n=2,339): 28.3% mean weight loss on 12 mg (efficacy estimand); 45.3% of the 12 mg group lost ≥30%.

   Lilly/PR Newswire — TRIUMPH-1 results
10. Apr 1, 2026Competitor
    Foundayo (orforglipron) approved — Lilly's pricing precedent

    Approved under the National Priority Voucher program. LillyDirect self-pay $149–$349/month; $25/month for eligible commercially insured patients.

    PharmExec — Foundayo approval
11. Mar 31, 2026Enforcement
    FDA warning letter: Gram Peptides ("GLP-1-R")

    Seller marketed illicit retatrutide under a code name.

    FDA warning letters (GLP-1 Solution; Gram Peptides)
12. Dec 11, 2025Trial
    TRIUMPH-4 topline: 28.7% at 68 weeks; first Phase 3 success

    Obesity + knee osteoarthritis: 28.7% mean weight loss (12 mg); WOMAC pain reduced by up to 75.8%.

    Lilly — TRIUMPH-4 results
13. Sept 9, 2025Enforcement
    FDA warning letter: GLP-1 Solution
    FDA warning letters (GLP-1 Solution; Gram Peptides)
14. Sept 2024Legal
    Lilly sues FDA over biologic classification

    Lilly plans a BLA; the FDA classifies retatrutide as a drug (NDA). Under an NDA, exclusivity would be 5 years.

    BioSpace — BLA/NDA biologic dispute
15. Jun 2023Trial
    Phase 2 published in NEJM (~24% at 48 weeks)

    ~24.2% mean weight loss at 48 weeks on the highest dose.

    Jastreboff et al., NEJM 2023 (Phase 2)

Regulatory & access changelog

• Aug 3, 2026: Lilly opens expanded access program